We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.
Non-hormonal
Brisdelle (low-dose, FDA-approved for hot flashes)
The only SSRI with FDA approval specifically for moderate-to-severe vasomotor symptoms — useful when HRT is not an option.
Medically reviewed by Dr. Ana Lisa Carr, MD, MBA · Last reviewed 2026-05-10
Paroxetine is a selective serotonin reuptake inhibitor. The 7.5 mg formulation (Brisdelle) is FDA-approved specifically for moderate-to-severe vasomotor symptoms.
It is a primary alternative for women who cannot or choose not to take estrogen — particularly breast cancer survivors.
Modulates central serotonergic pathways involved in temperature regulation, reducing hot flash frequency and severity.
No. Brisdelle is a much lower dose (7.5 mg) than typical SSRI antidepressant dosing.
Medically reviewed by Dr. Ana Lisa Carr, MD, MBA
Board-Certified Family Medicine Physician · Lead Provider / Medical Reviewer
NPI 1689841744 · Last reviewed: May 10, 2026
Evidence-based treatment overview
Mood Changes →Evidence-based treatment overview
Anxiety →Evidence-based treatment overview
Hormone therapy
Micronized Progesterone →Hormone therapy
Testosterone (low-dose, female-physiologic) →Hormone therapy
Semaglutide →GLP-1 weight care
This page is educational and is not a substitute for a clinical evaluation. Whether any medication is appropriate for you depends on your full medical history. Kindr providers make individualized prescribing decisions during a clinical visit.